Insider Selling: Outset Medical, Inc. (NASDAQ:OM) General Counsel Sells $26,344.00 in Stock

Outset Medical, Inc. (NASDAQ:OM) General Counsel John L. Brottem sold 32,930 shares of Outset Medical stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $0.80, for a total value of $26,344.00. Following the sale, the general counsel now directly owns 181,188 shares in the company, valued at $144,950.40. The trade was a 15.38 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Outset Medical Stock Down 1.1 %

Shares of Outset Medical stock opened at $0.85 on Friday. The firm’s 50-day moving average price is $1.01 and its two-hundred day moving average price is $1.26. The company has a quick ratio of 5.04, a current ratio of 6.49 and a debt-to-equity ratio of 4.12. Outset Medical, Inc. has a 1-year low of $0.44 and a 1-year high of $5.22.

Institutional Investors Weigh In On Outset Medical

A number of large investors have recently bought and sold shares of OM. Vanguard Personalized Indexing Management LLC acquired a new position in Outset Medical in the second quarter worth $49,000. Huntington National Bank grew its stake in shares of Outset Medical by 46.2% during the third quarter. Huntington National Bank now owns 63,306 shares of the company’s stock valued at $43,000 after purchasing an additional 20,000 shares during the last quarter. National Bank of Canada FI grew its stake in shares of Outset Medical by 79.2% during the third quarter. National Bank of Canada FI now owns 52,407 shares of the company’s stock valued at $35,000 after purchasing an additional 23,164 shares during the last quarter. Squarepoint Ops LLC increased its holdings in shares of Outset Medical by 74.1% in the second quarter. Squarepoint Ops LLC now owns 80,300 shares of the company’s stock valued at $309,000 after purchasing an additional 34,187 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Outset Medical in the 2nd quarter worth approximately $259,000.

Analyst Ratings Changes

Separately, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $3.00 price target on shares of Outset Medical in a research note on Tuesday, January 7th.

About Outset Medical

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.